Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AVI-6002 + AVI-6003
- Development stage
- Unknown
- Lead developer
- Sarepta Therapeutics
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous
01
Overview
**AVI-6002 + AVI-6003** is an experimental combination therapy developed by Sarepta Therapeutics (formerly AVI BioPharma) consisting of two phosphorodiamidate morpholino oligomers (PMOplus): AVI-6002 (AVI-7537 + AVI-7539) targeting Ebola virus VP24 and VP35 viral proteins, and AVI-6003 (AVI-7287 + AVI-7288) targeting Marburg virus VP24 and NP viral proteins. These antisense oligonucleotides inhibit viral replication by sterically blocking translation of target viral mRNA. It underwent Phase 1 single-ascending-dose safety and pharmacokinetic studies in healthy volunteers, showing good tolerability up to 4.5 mg/kg per component via IV infusion, with dose-proportional PK and plasma half-life of 2-5 hours; no maximum tolerated dose was reached. Supported by DoD funding, it demonstrated efficacy in nonhuman primate models of Ebola and Marburg hemorrhagic fevers, though development shifted to single agents AVI-7537 and AVI-7288.[1][2][3]
02
Targets
VP35 (Ebola virus VP35)NP (Taï Forest ebolavirus nucleoprotein)VP24 (Ebola virus VP24)
Beyond the preview
Go deeper on AVI-6002 + AVI-6003.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AVI-6002 + AVI-6003.